FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended MARCH 31, 2006
--------------
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
------------ -------------
Commission file number 0-10248
-------
FONAR CORPORATION
------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 11-2464137
------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
110 Marcus Drive Melville, New York 11747
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (631) 694-2929
---------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES X NO
--- ---
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). YES X NO
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the close of the latest practicable date.
Class Outstanding at April 30, 2006
- ----------------------------------------- -----------------------------
Common Stock, par value $.0001 112,649,862
Class B Common Stock, par value $.0001 3,953
Class C Common Stock, par value $.0001 9,562,824
Class A Preferred Stock, par value $.0001 7,836,287
FONAR CORPORATION AND SUBSIDIARIES
INDEX
PART I - FINANCIAL INFORMATION PAGE
----
Item 1. Financial Statements
Condensed Consolidated Balance Sheets - March 31, 2006
(Unaudited) and June 30, 2005 3
Condensed Consolidated Statements of Operations for
the Three Months Ended March 31, 2006 and
March 31, 2005 (Unaudited) 6
Condensed Consolidated Statements of Operations for
the Nine Months Ended March 31, 2006 and
March 31, 2005 (Unaudited) 7
Condensed Consolidated Statements of Comprehensive
Loss for the Three Months Ended
March 31, 2006 and March 31, 2005 (Unaudited) 8
Condensed Consolidated Statements of Comprehensive
(Loss) Income for the Nine Months Ended
March 31, 2006 and March 31, 2005 (Unaudited) 8
Condensed Consolidated Statements of Cash Flows for
the Nine Months Ended March 31, 2006 and
March 31, 2005 (Unaudited) 9
Notes to Condensed Consolidated Financial Statements (Unaudited) 11
Item 2. Management's Discussion and Analysis of Financial Condition 26
and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
Item 2. Changes in Securities
Item 3. Defaults Upon Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
Signatures
Exhibit - 31.1
Exhibit - 32.1
Page 2
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
ASSETS March 31, June 30,
2006 2005
(UNAUDITED)
Current Assets: --------- -------
Cash and cash equivalents $ 3,589 $ 5,517
Marketable securities 6,404 9,411
Accounts receivable - net 4,366 1,971
Accounts receivable - related parties - net 540 470
Medical receivables 6,880 9,990
Management fee receivable - 894
Management fee receivable - related medical
practices - net 7,385 7,826
Costs and estimated earnings in excess
of billings on uncompleted contracts 4,476 10,538
Inventories 7,656 9,838
Investment in sales-type lease 324 174
Current portion of advances and notes to related
medical practices 124 149
Current portion of note receivable less discount
for below market interest 331 -
Prepaid expenses and other current assets 1,310 1,785
------ ------
Total Current Assets 43,385 58,563
------ ------
Property and equipment - net 6,472 7,594
Advances and notes to related medical practices - net 706 201
Investment in sales-type lease - 279
Notes receivable less discount for below market interest 5,872 553
Management agreements - net - 3,992
Other intangible assets - net 4,903 4,503
Other assets 379 409
-------- --------
Total Assets $ 61,717 $ 76,094
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 3
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
March 31, June 30,
LIABILITIES AND STOCKHOLDERS' EQUITY 2006 2005
(UNAUDITED)
Current Liabilities: ---------- --------
Current portion of long-term debt and capital leases $ 229 $ 425
Accounts payable 4,801 8,468
Other current liabilities 6,524 7,474
Unearned revenue on service contracts 4,963 3,305
Unearned revenue on service contracts - related parties 484 526
Customer advances 3,476 1,633
Customer advances - related party 42 42
Income taxes payable - 11
Billings in excess of costs and estimated earnings on
uncompleted contracts 938 301
Billings in excess of costs and estimated earnings on
uncompleted contracts - related parties 255 153
------ ------
Total Current Liabilities 21,712 22,338
Long-Term Liabilities:
Due to related medical practices 100 128
Long-term debt and capital leases, less current portion 1,143 966
Other liabilities 232 270
------ ------
Total Long-Term Liabilities 1,475 1,364
------ ------
Total Liabilities 23,187 23,702
------ ------
Minority interest 688 523
------ ------
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 4
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED, except share data)
March 31, June 30,
LIABILITIES AND STOCKHOLDERS' EQUITY 2006 2005
(continued) (UNAUDITED)
------------ --------
STOCKHOLDERS' EQUITY
Class A non-voting preferred stock $.0001 par value;
8,000,000 authorized, 7,836,287 issued and outstanding
at March 31, 2006 and June 30, 2005 1 1
Common Stock $.0001 par value; 150,000,000 and 130,000,000
shares authorized at March 31, 2006 and June 30, 2005,
respectively; 112,468,316 issued at March 31, 2006 and
105,043,014 at June 30, 2005; 112,177,252 outstanding at
March 31, 2006 and 104,751,950 at June 30, 2005 11 10
Class B Common Stock $ .0001 par value; 4,000,000
shares authorized, (10 votes per share), 3,953 issued
and outstanding at March 31, 2006 and June 30, 2005 - -
Class C Common Stock $.0001 par value; 10,000,000 shares
authorized, (25 votes per share), 9,562,824 issued
and outstanding at March 31, 2006 and June 30, 2005 1 1
Paid-in capital in excess of par value 167,161 159,929
Accumulated other comprehensive loss ( 279) ( 182)
Accumulated deficit (127,401) (106,369)
Notes receivable from employee stockholders ( 868) ( 846)
Unearned compensation ( 109) -
Treasury stock, at cost - 291,064 shares of common stock
at March 31, 2006 and June 30, 2005 ( 675) ( 675)
------- -------
Total Stockholders' Equity 37,842 51,869
------- -------
Total Liabilities and Stockholders' Equity $ 61,717 $ 76,094
======= =======
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 5
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
FOR THE THREE MONTHS ENDED
MARCH 31,
---------------------
2006 2005
REVENUES -------- --------
Product sales - net $ 1,285 $15,550
Product sales - related parties - net 397 1,743
Service and repair fees - net 2,079 1,361
Service and repair fees - related parties - net 250 201
Management and other fees - related medical
practices - net 3,092 5,890
License fees and royalties - 585
-------- --------
Total Revenues - Net 7,103 25,330
-------- --------
COSTS AND EXPENSES
Costs related to product sales 1,558 9,966
Costs related to product sales - related parties 546 1,053
Costs related to service and repair fees 1,291 1,224
Costs related to service and repair fees - related parties 153 166
Costs related to management and other
fees - related medical practices 2,051 3,657
Research and development 1,683 1,482
Selling, general and administrative,
inclusive of compensatory element of stock
issuances of $ 268 and $ 771 for the three months
ended March 31, 2006 and 2005, respectively 6,404 7,599
Provision for bad debts 775 50
Amortization of management agreements - 158
-------- --------
Total Costs and Expenses 14,461 25,355
-------- --------
Loss From Operations ( 7,358) ( 25)
Interest Expense ( 50) ( 47)
Investment Income 207 133
Interest Income - Related Parties 3 6
Other Income (Expense) 44 ( 305)
Minority Interest in Income of Partnerships ( 203) ( 231)
------ -------
Loss Before Provision for Income Taxes ( 7,357) ( 469)
Provision for Income Taxes - 11
------- -------
NET LOSS $( 7,357) $( 480)
======= =======
Net Loss Available to Common Stockholders $( 7,357) $ ( 480)
------- -------
Basic Loss Per Common Share $ ( .07) $ -
======== ========
Diluted Loss Per Common Share $ ( .07) $ -
======== ========
Basic and Diluted Earnings Per Share-Common C N/A N/A
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 6
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
FOR THE NINE MONTHS ENDED
MARCH 31,
---------------------
2006 2005
REVENUES -------- --------
Product sales -net $ 7,125 $51,832
Product sales - related parties -net 2,914 4,621
Service and repair fees -net 5,617 3,473
Service and repair fees - related parties -net 740 574
Management and other fees - net 648 -
Management and other fees -related medical practices -net 9,526 17,642
License fees and royalties 1,227 1,755
-------- --------
Total Revenues - Net 27,797 79,897
-------- --------
COSTS AND EXPENSES
Costs related to product sales 7,065 33,005
Costs related to product sales - related parties 2,540 2,666
Costs related to service and repair fees 3,722 3,277
Costs related to service and repair
fees - related parties 490 521
Costs related to management and other fees 528 -
Costs related to management and other
fees - related medical practices 6,724 10,911
Research and development 5,248 4,305
Selling, general and administrative, inclusive
of compensatory element of stock issuances of
$ 1,337 and $ 2,475 for the nine months ended
March 31, 2006 and 2005, respectively 19,954 22,481
Provision for bad debts 825 150
Amortization of management agreements 37 475
Termination costs paid with common stock 1,600 -
--------- --------
Total Costs and Expenses 48,733 77,791
--------- --------
(Loss) Income From Operations (20,936) 2,106
Interest Expense ( 214) ( 179)
Investment Income 617 394
Interest Income - Related Parties 9 19
Other Income (Expense) 262 ( 162)
Minority Interest in Income of Partnerships ( 769) ( 678)
-------- --------
(Loss) Income Before Provision for Income Taxes (21,031) 1,500
Provision for Income Taxes - 53
-------- --------
NET (LOSS) INCOME $(21,031) $ 1,447
======== ========
Net (Loss) Income Available to Common Stockholders $(21,031) $ 1,346
-------- --------
Basic (Loss) Earnings Per Common Share $ ( .19) $ .01
======== ========
Diluted (Loss) Earnings Per Common Share $ ( .19) $ .01
======== ========
Basic and Diluted Earnings Per Share-Common C N/A -
========= ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 7
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)
(000'S OMITTED)
FOR THE THREE MONTHS ENDED
MARCH 31,
-----------------
2006 2005
------ ------
Net loss $(7,357) $( 480)
Other comprehensive income (loss), net of tax:
Unrealized gains (losses) on securities,
net of tax 50 ( 146)
------- -------
Total comprehensive loss $(7,307) $( 626)
======= =======
FOR THE NINE MONTHS ENDED
MARCH 31,
-----------------
2006 2005
------ ------
Net (loss) income $(21,031) $ 1,447
Other comprehensive loss, net of tax:
Unrealized losses on securities,
net of tax ( 97) ( 137)
------ ------
Total comprehensive (loss) income $(21,128) $ 1,310
====== ======
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 8
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(000'S OMITTED)
FOR THE NINE MONTHS ENDED
MARCH 31,
-----------------
2006 2005
------ ------
Cash Flows from Operating Activities:
Net (loss) income $(21,031) $ 1,447
Adjustments to reconcile net (loss) income to
net cash used in operating activities:
Minority interest in income of partnerships 769 678
Depreciation and amortization 2,430 2,929
Provision for bad debts 825 150
Compensatory element of stock issuances 1,337 2,475
Stock issued for costs and expenses 3,001 4,290
Termination costs paid with common stock 1,600 -
Amortization of unearned compensation 291 -
Reduction in notes receivable from employee
stockholders adjusted to compensation 88 126
Gain on sale of equipment ( 3) ( 28)
Amortization of unearned license fee - ( 1,755)
Loss from sale of physical medicine
management business 144 -
(Increase) decrease in operating assets, net:
Accounts and management fee receivable ( 630) ( 2,207)
Notes receivable ( 3) -
Costs and estimated earnings in excess of
billings on uncompleted contracts 6,062 ( 4,913)
Inventories 2,182 ( 456)
Principal payments received on sales type lease 128 113
Prepaid expenses and other current assets 475 ( 425)
Other assets 26 ( 6)
Advances and notes to related medical practices ( 27) 206
Increase (decrease) in operating liabilities, net:
Accounts payable ( 3,655) 697
Other current liabilities 745 2,747
Customer advances 1,843 ( 4,248)
Billings in excess of costs and estimated
earnings on uncompleted contracts 739 ( 2,095)
Other liabilities ( 38) ( 18)
Due to related medical practices ( 28) -
Income taxes payable ( 11) ( 26)
------ ------
Net cash used in operating activities ( 2,741) ( 319)
------ ------
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 9
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(000'S OMITTED)
FOR THE NINE MONTHS ENDED
MARCH 31,
-------------------
2006 2005
------- -------
Cash Flows from Investing Activities:
Purchases of marketable securities ( 300) (11,745)
Sales of marketable securities 3,210 12,178
Purchases of property and equipment ( 1,592) ( 1,638)
Costs of capitalized software development ( 557) ( 605)
Cost of patents and copyrights ( 371) ( 306)
Proceeds from sale of equipment 97 31
------ ------
Net cash provided by (used in) investing activities 487 ( 2,085)
------ ------
Cash Flows from Financing Activities:
Distributions to holders of minority interests ( 604) ( 610)
Proceeds from long-term debt 478 -
Restricted cash - 5,500
Repayment of long-term and capital
leases ( 255) ( 5,854)
Proceeds from exercise of stock options
and warrants 662 254
Collection of notes receivable from employee
stockholders 45 31
------ ------
Net cash provided by (used in) financing activities 326 ( 679)
------ ------
Net Decrease in Cash and Cash Equivalents (1,928) ( 3,083)
Cash and Cash Equivalents - Beginning of Period 5,517 9,474
------ ------
Cash and Cash Equivalents - End of Period $ 3,589 $ 6,391
====== ======
Supplemental Cash Flow Information:
During the nine months ended March 31, 2006 and March 31, 2005, the Company
paid $214,000 and 179,000 for interest, respectively.
Non-Cash Transaction
During the nine months ended March 31, 2006:
a) The Company acquired equipment of $132,000 under capital lease obligations.
See accompanying notes to condensed consolidated financial statements
(unaudited).
Page 10
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION & LIQUIDITY & CAPITAL RESOURCES
Basis of Presentation
- ---------------------
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by accounting principles generally accepted in the United
States of America for complete financial statements. In the opinion of
management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included. Operating results for the
nine months ended March 31, 2006 are not necessarily indicative of the results
that may be expected for the fiscal year ending June 30, 2006. For further
information, refer to the consolidated financial statements and footnotes
thereto included in the Company's Annual Report on Form 10-K filed on September
28, 2005 for the fiscal year ended June 30, 2005.
Liquidity and Capital Resources
- -------------------------------
Our principal source of liquidity has been cash flows provided by operations. We
currently expect this to continue. At March 31, 2006, we had working capital of
$21.7 million. For the nine months ended March 31, 2006, we incurred a net loss
of $21 million which included non-cash charges of $10.4 million.
In order to conserve our capital resources we have and will continue to issue,
from time to time, common stock and stock options to compensate employees and
non-employees for services rendered. The Company is focusing on increased
advertising and marketing campaigns and distribution programs to increase the
demand for Fonar's products. Management anticipates that Fonar's capital
resources will improve as Fonar's MRI scanner products gain wider market
recognition and acceptance resulting in increased product sales.
Given our March 31, 2006 cash and marketable securities balance of $9.9 million
and our forecasted cash requirements, we anticipate that our existing capital
resources, funds generated from operations and funds expected to be received
from note repayments, will be sufficient to satisfy our cash flow requirements
through at least March 31, 2007. Should sales be less than forecast and expenses
higher than anticipated, the Company may need to seek alternative sources of
funds through the issuance of equity or debt financing or other alternatives
including streamlining operations.
Page 11
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
- ---------------------------
The consolidated financial statements include the accounts of FONAR Corporation,
its majority and wholly-owned subsidiaries and partnerships (collectively the
"Company"). All significant intercompany accounts and transactions have been
eliminated in consolidation.
Earnings (Loss) Per Share
- -------------------------
Basic earnings (loss) per share ("EPS") is computed based on weighted average
shares outstanding and excludes any potential dilution. In accordance with EITF
03-6, "Participating Securities and the Two-Class method under FASB Statement
No. 128" ("EITF 03-6"), the Company's participating convertible securities,
which include Class B common stock and Class C common stock, are not included in
the computation of basic EPS for nine months ended March 31, 2006 and the three
months ended March 31, 2006 and 2005, because the participating securities do
not have a contractual obligation to share in the losses of the Company. For the
nine months ended March 31, 2005, the Company used the Two-Class method for
calculating basic earnings per share and applied the if converted method in
calculating diluted earnings per share.
Diluted EPS reflects the potential dilution from the exercise or conversion of
all dilutive securities into common stock based on the average market price of
common shares outstanding during the period. The number of common shares
potentially issuable upon the exercise of certain options and warrants or
conversion of the participating convertible securities that were excluded from
the diluted EPS calculation was approximately 7,025,000 because they are
antidilutive as a result of a net loss for the three and nine months ended March
31, 2006. For the three and nine months ended March 31, 2005, the number of
common shares potentially issuable upon the exercise of certain options of
669,000 have not been included in the computation of diluted EPS since the
effect would be antidilutive.
Page 12
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Earnings (Loss) Per Share (Continued)
- -------------------------
Three Months Three Months
ended March 31, ended March 31,
2006 2005
(000's omitted, except per share data)
Class C
Common Common
Total Total Stock Stock
------------------ -------- -------- --------
Basic
Numerator:
Net loss available
to common stockholders $(7,357) $ (480) $ (480) $ -
================== ======== ======== =========
Denominator:
Weighted average shares
outstanding 111,522 102,543 9,563
================== ======== =========
Basic loss per
common share$ (.07) $ .-- $ .-- $ .--
================== ======== ======== =========
Diluted
Weighted average
shares outstanding 111,522 102,543 102,543
Stock options - - -
Warrants - - -
Convertible Class C
common stock - - -
------------------ -------- --------
- ---
Denominator for diluted earnings per share:
Weighted average shares
outstanding of common
stock and equivalents 111,522 102,543 102,543
================== ======== ========
Diluted loss per
common share $ (.07) $ -- $ --
================== ======== ========
Page 13
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Earnings (Loss) Per Share (Continued)
- -------------------------
Nine Months Nine Months
ended March 31, ended March 31,
2006 2005
(000's omitted, except per share data)
Class C
Common Common
Total Total Stock Stock
------------------ -------- -------- --------
Basic
Numerator:
Net (loss) income available to
common stockholders$ (21,031) $ 1,346 $ 1,314 $ 32
================== ======== ======== =========
Denominator:
Weighted average
shares outstanding 109,606 100,731 9,563
================== ======== ========
Basic (loss) income
per common share $ (.19) $ .01 $ .01 $ .--
================== ======== ======== ========
Diluted
Weighted average
shares outstanding 109,606 100,731 100,731
Stock options - 273 273
Warrants - 536 536
Convertible Class C
common stock - 3,188 3,188
------------------ -------- --------
Denominator for diluted earnings
per share:
Weighted average shares
outstanding of common
stock and equivalents 109,606 104,728 104,728
================== ======== ========
Diluted (loss) income
per common share $ (.19) $ .01 $ .01
================== ======== ========
Page 14
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Stock Options and Warrants and Similar Equity Instruments
- ---------------------------------------------------------
In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share-Based
Payment" SFAS 123R. SFAS 123R requires the compensation cost relating to
stock-based payment transactions be recognized in financial statements. That
cost will be measured based on the fair value of the equity or liability
instruments issued on the grant date of such instruments, and will be recognized
over the period during which an individual is required to provide service in
exchange for the award (typically the vesting period). SFAS 123R covers a wide
range of stock-based compensation arrangements including stock options,
restricted stock plans, performance-based awards, stock appreciation rights, and
employee stock purchase plans. SFAS 123R replaces SFAS 123 and supersedes APB
Opinion 25. In April 2005, the Securities and Exchange Commission delayed the
effective date of SFAS 123R to the first interim or annual reporting period of
the Company's first fiscal year beginning on or after June 15, 2005. Early
adoption will be permitted in periods in which financial statements have not yet
been issued. The Company has adopted SFAS 123R as of July 1, 2005. As of June
30, 2005 all options were fully vested and during the nine months ended March
31, 2006 the Company granted to an employee 50,000 options to purchase common
stock at an exercise price of $1.00. Accordingly, no additional compensation
charge was required because the value of these options was determined to be
diminimus and therefore there was no impact on the condensed consolidated
financial statements upon the adoption of this pronouncement.
SFAS 123R permits public companies to adopt its requirement using one of two
methods: 1) A "modified prospective" method in which compensation cost is
recognized beginning with the effective date (a) based on the requirements of
SFAS 123R for all share-based payments granted after the effective date and (b)
based on the fair value as measured under SFAS 123 for all awards granted to
employees prior to the effective date of SFAS 123R that remain unvested on the
effective date; or 2) A "modified retrospective" method which includes the
requirements of the modified prospective method described above, but also
permits entities to restate based on the amounts previously recognized under
SFAS 123 for purposes of pro forma disclosures either (a) all prior periods
presented or (b) to the start of the fiscal year in which SFAS 123R is adopted.
The Company adopted SFAS 123R using the modified prospective method.
Accordingly, the adoption of SFAS 123R's fair value method did not have a
significant impact on our result of operations. However, had the Company adopted
SFAS 123R in prior periods, the impact of that standard would have approximated
the impact of SFAS 123 as described in the disclosure of pro forma net loss and
loss per share in Note 2 to our condensed consolidated financial statements.
SFAS 123R also requires the benefits of tax deductions in excess of recognized
compensation cost to be reported as a financing cash flow, rather than as an
operating cash flow as required under current literature. It is unlikely that
the Company will have near term benefits from tax deductions. This requirement
will reduce net operating cash flows and increase net financing cash flows in
periods after adoption. The Company cannot estimate what those amounts will be
in the future because of various factors, including but not limited to the
timing of employee exercises and whether the Company will be in a taxable
position. At this time, there would be no tax impact related to the prior
periods since the Company has a net loss.
Page 15
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Stock Options and Warrants and Similar Equity Instruments (Continued)
- ---------------------------------------------------------
For the period ending prior to July 1, 2005, as permitted under Statement of
Financial Accounting Standard ("SFAS") No. 148, "Accounting for Stock-Based
Compensation--Transition and Disclosure", which amended SFAS No. 123 ("SFAS
123"), "Accounting for Stock-Based Compensation", the Company had elected to
continue to follow the intrinsic value method in accounting for its stock-based
employee compensation arrangements as defined by Accounting Principles Board
Opinion ("APB") No. 25. "Accounting for Stock Issued to Employees", and related
interpretations including Financial Accounting Standards Board ("FASB")
Interpretation No. 44, "Accounting for Certain Transactions Involving Stock
Compensation", an interpretation of APB No. 25. No stock-based employee
compensation cost is reflected in operations, as all options granted under those
plans had an exercise price equal to the market value of the underlying common
stock on the date of grant.
The following table illustrates the effect on net income and earnings per share
if the Company had applied the fair value recognition provisions of SFAS 123 to
stock-based employee compensation for the three and nine months ended March 31,
2005:
For the Three Months For the Nine Months
Ended March 31, 2005 Ended March 31, 2005
(000's omitted, except (000's omitted, except
per share data) per share data)
---------------------- ----------------------
Net (loss) income available
to common shareholders $(480) $ 1,346
Less:
Undistributed earnings allocated -- 32
to Class C common stock ---------------------- ----------------------
(480) 1,314
Less:
Total stock-based employee compensation
expense determined under fair value 142 150
based method for all awards ---------------------- ----------------------
Pro forma Net (Loss) Income $(622) $1,164
====================== ======================
Basic Net (Loss) Income Per Share $ -- $ 0.01
as Reported ====================== ======================
Basic Pro forma Net (Loss) Income $(0.01) $ 0.01
per Share ====================== ======================
Diluted Net (Loss) Income per share $ -- $ 0.01
as reported ====================== ======================
Diluted Pro Forma Net (Loss) Income $(0.01) $ 0.01
per share ====================== ======================
Page 16
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Stock Options and Warrants and Similar Equity Instruments (Continued)
- ---------------------------------------------------------
The fair value of options at date of grant was estimated using the Black-
Scholes fair value based method with the following weighted average assumptions:
For the Three and Nine Months Ended
March 31, 2005
-----------------------------------
Expected life (years) 3
Interest Rate 2.69%
Annual Rate of dividends 0%
Volatility 55%
Recent Accounting Pronouncements
In May 2005, the FASB issued Statement No. 154, Accounting Changes and
Error Corrections-A Replacement of APB Opinion No. 20 and SFAS No. 3. SFAS No.
154 changes the requirements for the accounting and reporting of a change in
accounting principle be requiring retrospective application to prior periods'
financial statements of the change in accounting principle, unless it is
impracticable to do so. SFAS No. 154 also requires that a change in depreciation
or amortization for long-lived, non-financial assets be accounted for as a
change in accounting estimate effected by a change in accounting principle. SFAS
No. 154 is effective for accounting changes and corrections of errors made in
fiscal years beginning after December 15, 2005. We adopted SFAS No. 154 on
January 1, 2006. This adoption had no effect on our consolidated financial
statements.
In February 2006, the FASB issued SFAS NO. 155, Accounting for Certain
Hybrid Financial Instruments-An Amendment of FASB No. 133 and 140. The purpose
of SFAS statement No. 155 is to simplify the accounting for certain hybrid
financial instruments by permitting fair value re-measurement for any hybrid
financial instrument that contains an embedded derivative that otherwise would
require bifurcation. SFAS No. 155 also eliminates the restriction on passive
derivative instruments that a qualifying special-purpose entity may hold. SFAS
No. 155 is effective for all financial instruments acquired or issued after the
beginning of any entity's first fiscal year beginning after September 15, 2006.
We believe that the adoption of this standard on July 1, 2007 will not have a
material effect on our consolidated financial statements.
In March 2006, the FASB issued SFAS No. 156, Accounting for Servicing of
Financial Assets, an Amendment of SFAS No. 140. SFAS No. 156 requires separate
recognition of a servicing asset and a servicing liability each time an entity
undertakes and obligation to service a financial asset by entering into a
servicing contract. This statement also requires that servicing assets and
liabilities be initially recorded at fair value and subsequently adjusted to the
fair value at the end of each reporting period. This statement is effective in
fiscal years beginning after September 15, 2006. We believe that the adoption of
this standard on July 1, 2007 will not have a material effect on our
consolidated financial statements.
Page 17
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 3 - ACCOUNTS RECEIVABLE AND MEDICAL RECEIVABLES
Accounts Receivable
- -------------------
Accounts receivable, net is comprised of the following at March 31, 2006:
(000's Omitted)
Gross Allowance for
Receivable doubtful accounts Net
---------- ----------------- ---------
Receivables from equipment
sales and service contracts $ 4,864 $ 498 $ 4,366
========== ================= =========
Receivables from equipment
sales and service contracts-
related parties $ 1,186 $ 646 $ 540
========== ================= =========
Management fee receivables from
related medical practices ("PC's") $ 9,936 $ 2,551 $ 7,385
========== ================= =========
Medical Receivables
- -------------------
The Company was assigned medical receivables valued at $11,775,000, in
connection with the satisfaction of the management fees and termination fees
related to a Termination and Replacement Agreement dated May 23, 2005. The
balance of the medical receivables as of March 31, 2006 was $6,880,000.
The Company's customers are concentrated in the healthcare industry.
The Company's receivables from the related PC's consist substantially of fees
outstanding under management agreements, service contracts and lease agreements.
Payment of the outstanding fees is based on collection by the PC's of fees from
third party medical reimbursement organizations, principally insurance companies
and health management organizations.
Collection by the Company of its accounts receivable may be impaired by the
uncollectibility of the PC's medical fees from third party payors, particularly
insurance carriers covering automobile no-fault and workers compensation claims
due to longer payment cycles and rigorous informational requirements and certain
other disallowed claims. Approximately 48% and 65% of the PC's net revenues for
both the nine months ended March 31, 2006 and 2005, respectively, were derived
from no-fault and personal injury protection claims. The Company considers the
aging of its accounts receivable in determining the amount of allowance for
doubtful accounts and contractual allowances. The Company generally takes all
legally available steps to collect its receivables. Credit losses associated
with the receivables are provided for in the condensed consolidated financial
statements and have historically been within management's expectations.
Page 18
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 3 - ACCOUNTS RECEIVABLE AND MEDICAL RECEIVABLES (Continued)
Medical Receivables (Continued)
- -------------------
Net revenues from management and other fees charged to the related P.C's
accounted for approximately 43.5% and 23.3% of the consolidated net revenues for
the three months ended March 31, 2006 and 2005, respectively. Product sales and
service repair fees from related parties amounted to approximately 9.1% and 7.7%
of consolidated net revenues for the three months ended March 31, 2006 and 2005,
respectively.
Net revenues from management and other fees charged to the related PC's
accounted for approximately 34.3% and 22.1% of the consolidated net revenues for
the nine months ended March 31, 2006 and 2005, respectively. Product sales and
service and repair fees from related parties amounted to approximately 13.1% and
6.5% of consolidated net revenues for the nine months ended March 31, 2006 and
2005, respectively.
Unaudited Financial Information of Unconsolidated Managed Medical Practices
- ---------------------------------------------------------------------------
Summarized income statement data for the three months ended March 31, 2006
related to the 12 unconsolidated medical practices managed by the Company is as
follows:
(000's omitted) (Income Tax-Cash Basis)
Patient Revenue - Net $ 4,189
=======
Income from Operations $ 13
=======
Net Loss $ (183)
=======
Summarized income statement data for the nine months ended March 31, 2006
related to the 12 unconsolidated medical practices managed by the Company is as
follows:
(000's omitted) (Income Tax-Cash Basis)
Patient Revenue - Net $ 12,587
========
Income from Operations $ 123
========
Net Loss $ (497)
========
Page 19
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 4 - INVENTORIES
Inventories included in the accompanying condensed consolidated balance sheet at
March 31, 2006 consist of:
(000's omitted)
Purchased parts, components
and supplies $ 5,052
Work-in-process 2,604
-------
$ 7,656
=======
NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS AND CUSTOMER
ADVANCES
1) Information relating to uncompleted contracts as of March 31,
2006 is as
follows:
(000's omitted)
Costs incurred on uncompleted contracts $ 13,160
Estimated earnings 6,295
--------
19,455
Less: Billings to date 16,172
-------
$ 3,283
========
Included in the accompanying condensed consolidated balance sheet at March 31,
2006 under the following captions:
Costs and estimated earnings in excess of
billings on uncompleted contracts $ 4,476
Less: Billings in excess of costs and estimated
earnings on uncompleted contracts 938
Billings in excess of costs and estimated
earnings on uncompleted contracts - related parties 255
--------
$ 3,283
========
2) Customer advances consist of the following as of March 31, 2006:
Related
Total Party Other
--------- ---------- ---------
Total Advances $ 19,690 $ 2,992 $ 16,698
Less: Advances
on contracts under construction 16,172 2,950 13,222
--------- ---------- ---------
$ 3,518 $ 42 $ 3,476
========= ========== =========
Page 20
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 6 - LOAN PAYABLE
On November 29, 2005, HMCA purchased a building in Tallahassee, Florida. The
total purchase price, including closing costs was $437,644. The purchase price
was funded by a loan of $500,000 of which $391,974 was used towards the purchase
price. As of March 31, 2006 there was an unused portion of the loan of $21,026
which is to be used for future construction costs relating to the building.
The loan requires monthly payments of interest at a rate of 7% until May 29,
2009 followed by payments of $3,908 per month until May 29, 2026. A final
payment of the entire unpaid portion of principal and interest will be due on
May 29, 2026.
NOTE 7 -STOCKHOLDERS' EQUITY
Common Stock
During the three months ended March 31, 2006:
a) The Company issued 257,585 shares of common stock to employees as
compensation valued at $187,160 under stock bonus plans.
b) The Company issued 88,763 shares of common stock to consultants and others
valued at $61,522.
c) The Company issued 199,124 shares of common stock for costs and expenses of
$130,255.
d) The Company issued 243,715 shares of common stock upon the exercise of
stock options resulting in proceeds of $161,740.
e) The Company issued 240,000 shares of common stock valued at $148,800 in
connection with issuance of notes receivable from employee stockholders.
Common Stock
During the nine months ended March 31, 2006:
a) The Company issued 853,574 shares of common stock to employees as
compensation valued at $789,310 under stock bonus plans.
b) The Company issued 521,218 shares of common stock to consultants and others
valued at $471,015.
c) The Company issued 3,075,305 shares of common stock for costs and expenses
of $3,000,813.
d) The Company issued 753,715 shares of common stock upon the exercise of
stock options resulting in proceeds of $661,740.
e) The Company issued 1,871,490 shares of common stock for termination costs
and collection service valued at $1,995,675.
f) The Company issued 350,000 shares of common stock valued at $237,800 in
connection with issuance of notes receivable from employee stockholders.
Options
- -------
During the nine months ended March 31, 2006, the Company granted to a financial
consultant 703,000 options to purchase common stock at exercise prices ranging
from $.63 to $1.00 per share. During the nine months ended March 31, 2006 the
consultant exercised all of the 703,000 options granted to him during the nine
months ended March 31, 2006.
Page 21
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 8 -SALE OF PHYSICAL MEDICINE MANAGEMENT BUSINESS
On July 28, 2005 Fonar, HMCA and Dynamic entered into an Asset Purchase
Agreement with Health Plus Management Services, L.L.C. ("Health Plus"), pursuant
to which HMCA and its subsidiary Dynamic sold to Health Plus the portion of
their business which was engaged in the business of managing physical therapy
and rehabilitation facilities, together with the assets used in the conduct of
such business.
The assets sold consisted principally of the management agreements with the
physical therapy and rehabilitation facility management business, the physical
therapy equipment, a portion of the accounts receivable and furniture and
fixtures the Company provided to the physical therapy and rehabilitation
facilities.
The purchase price under the Asset Purchase Agreement was $6.6 million, payable
pursuant to a promissory note (the "note") in 120 monthly installments
commencing on August 28, 2005. The first twelve installments are interest only
and the remaining 108 payments will consist of equal installments of principal
and interest in the amount of $76,014 each. The note is secured by a first lien
on all of the assets of Health Plus, including its accounts receivable. The Note
is subject to prepayment provisions to the extent Health Plus resells all or
part of the assets and business or utilizes the assets sold as collateral in any
debt financing. The note provides for interest at 5% per annum. The fair value
assigned to the note was $6,078,068 reflecting a discount of $521,932 for the
below market interest rate. The Company recorded a loss of $143,598 on this
transaction during the nine months ended March 31, 2006.
The two principals of Health Plus were employed by HMCA and Dynamic up to the
time of the closing of the business. In consideration for the termination of
their employment agreement, these two individuals each became entitled to
receive $800,000. In addition, each became entitled to receive $200,000 for
collection services to be provided on behalf of HMCA and Dynamic with respect to
a portion of the accounts receivable of certain physical therapy and
rehabilitation facilities which arose during the period when HMCA was engaged in
the management of those facilities. The $1,000,000 payable to each of these
individuals was satisfied in shares of Fonar common stock. During the nine
months ended March 31, 2006 the Company issued 1,871,490 shares totaling
$1,995,675. The remaining balance under this obligation at March 31, 2006 is
$4,325 which was included in other current liabilities. The Company capitalized
$400,000 with respect to collection services which is being amortized over 11
months. During the nine months ended March 31, 2006, $290,909 was amortized and
the remaining balance of $109,091 is classified as unearned compensation.
For accounting purposes in accordance with accounting principles generally
accepted in the United States of America, the Company determined that the
classification of the disposed business described above as discontinued
operations would not be appropriate. Accordingly, the operating results of the
disposed business have been included in continuing operations in the
accompanying consolidated financial statements.
Page 22
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 8 -SALE OF PHYSICAL MEDICINE MANAGEMENT BUSINESS (Continued)
The following schedule shows the calculation of the loss on sale of the physical
medicine business:
Selling Price $ 6,600,000
Less: Discount for below market interest (521,932)
------------
Net selling price 6,078,068
Assets sold:
Management fee receivable $1,388,547
Property and equipment - net 444,230
Notes receivable 431,000
Management agreements - net 3,954,389
Security deposits 3,500
------------
Subtotal 6,221,666
------------
Loss on sale of business $ (143,598)
============
NOTE 9 - SALE OF SUBSIDIARY
On January 31, 2006, Raymond V. Damadian MR Scanning Centers entered into an
agreement to sell the stock of Tallahassee Magnetic Resonance Imaging, P.A. to
Raymond V. Damadian for a diminimus amount. No gain or loss was recognized on
this sale. Revenue recognized from this entity totaled $590,883 and $954,651 for
the nine month periods ended March 31, 2006 and 2005.
NOTE 10 - LICENSE FEES AND ROYALTIES
During the nine months ended March 31, 2006, the Company received a fee in the
amount of $1,227,000 from an independent licensee who had not met its annual
sales quota.
NOTE 11 - SEGMENT AND RELATED INFORMATION
The Company operates in two industry segments - manufacturing and the servicing
of medical equipment and management of physician practices, including diagnostic
imaging services.
The accounting policies of the segments are the same as those described in the
summary of significant accounting policies as disclosed in the Company's 10-K as
of June 30, 2005. All inter-segment sales are market-based. The Company
evaluates performance based on income or loss from operations.
Summarized financial information concerning the Company's reportable segments is
shown in the following table:
Page 23
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 11 - SEGMENT AND RELATED INFORMATION (CONTINUED)
(000's omitted)
Physician
Management and
Diagnostic
Medical Imaging
Equipment Services Totals
----------- ---------- ----------
For the three months ended March 31, 2006:
Net revenues from external customers $ 4,011 $ 3,092 $ 7,103
Inter-segment net revenues $ 152 $ --- $ 152
Loss from operations $ (6,290) $ (1,068) $ (7,358)
Depreciation and amortization $ 498 $ 273 $ 771
Compensatory element of stock issuances $ 254 $ 14 $ 268
Capital expenditures $ 413 $ 529 $ 942
For the three months ended March 31, 2005:
Net revenues from external customers $ 19,440 $ 5,890 $ 25,330
Inter-segment net revenues $ 114 $ -- $ 114
Income (loss) from operations $ (160) $ 135 $ (25)
Depreciation and amortization $ 562 $ 395 $ 957
Compensatory element of stock issuances $ 371 $ 400 $ 771
Capital expenditures $ 436 $ 357 $ 793
Physician
Management and
Diagnostic
Medical Imaging
Equipment Services Totals
----------- ---------- ----------
For the nine months ended March 31, 2006:
Net revenues from external customers $ 17,623 $ 10,174 $ 27,797
Inter-segment net revenues $ 429 $ -- $ 429
Loss from operations $ (16,846) $ (4,090) $ (20,936)
Depreciation and amortization $ 1,497 $ 933 $ 2,430
Compensatory element of stock issuances $ 1,010 $ 327 $ 1,337
Termination costs paid with common stock $ -- $ 1,600 $ 1,600
Capital expenditures $ 1,090 $ 1,430 $ 2,520
Identifiable assets $ 35,126 $ 26,591 $ 61,717
For the nine months ended March 31, 2005 :
Net revenues from external customers $ 62,255 $ 17,642 $ 79,897
Inter-segment net revenues $ 357 $ - $ 357
Income from operations $ 1,376 $ 730 $ 2,106
Depreciation and amortization $ 1,760 $ 1,169 $ 2,929
Compensatory element of stock issuances $ 1,152 $ 1,323 $ 2,475
Capital expenditures $ 1,425 $ 1,124 $ 2,549
Identifiable assets - June 30, 2005 $ 46,265 $ 29,829 $ 76,094
Page 24
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(UNAUDITED)
NOTE 12 - POTENTIAL DELISTING OF THE COMPANY'S COMMON STOCK
The Company received written notification from The Nasdaq Stock Market on
December 22, 2005 that the bid price of its common stock for the last 30
consecutive trading days had closed below the minimum $1.00 per share required
for continued listing under Nasdaq Marketplace Rule 4310(c)(4) (the "Rule").
Pursuant to Nasdaq Marketplace Rule 4310(c)(8)(D), the Company has been provided
an initial period of 180 calendar days, or until June 20, 2006, to regain
compliance. The notice states the Nasdaq staff (the "Staff") will provided
written notification that the Company has achieved compliance with the Rule if
at any time before June 20, 2006 the bid price of the Company's common stock
closes at $1.00 per share or more for a minimum of 10 consecutive business days.
If the Company cannot demonstrate compliance with the Rule by June 20, 2006, the
Staff will determine whether the Company meets the Nasdaq Capital Market initial
listing criteria as set forth in Marketplace Rule 4310(c), except for the bid
price requirement. If the Company meets the initial listing criteria, the Staff
will notify the Company that it has been granted an additional 180 calendar days
compliance period. FONAR currently complies with the requirements for initial
listing on The Nasdaq Capital Market, except for the $1.00 minimum closing bid
price. If the Company is not eligible for an additional compliance period, the
Staff will provide written notice that the Company's securities will be
delisted. At that time, the Company may appeal the Staff's determination to
delist its securities to a Listing Qualifications Panel.
NOTE 13 - SUBSEQUENT EVENT
Common Stock
- ------------
During the period from April 1, 2006 through April 30, 2006:
a) The Company issued 13,627 shares of common stock to employees as
compensation of $8,858 under stock bonus plans.
b) The Company issued 26,000 shares of common stock for costs and expenses of
$16,380.
c) The Company issued 408,339 shares of common stock upon the exercise of
stock options resulting in proceeds of $240,920.
d) The Company issued 24,644 shares of common stock to consultants and others
at a value of $ 15,526.
Page 25
FONAR CORPORATION AND SUBSIDIARIES
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
For the nine month period ended March 31, 2006, we reported a net loss of
$21.0 million on revenues of $27.8 million as compared to net income of $1.4
million on revenues of $79.9 million for the first nine months of fiscal 2005.
For the fiscal quarter ended March 31, 2006 (third quarter of fiscal 2006),
we reported a net loss of $7.4 million on revenues of $7.1 million as compared
to a net loss of $480,000 on revenues of $25.3 million for the third quarter of
fiscal 2005.
The losses were primarily due to increased marketing and advertising pressure
from our competitors attempting to minimize the unique medical benefits of
Upright MRI(TM), which companies may not make Upright MRI(TM) because of Fonar's
patents and a brief interruption in Fonar's advertising. In addition, we have
noticed a concern on the part of prospective customers relating to more
difficulty in obtaining insurance reimbursements. We have resumed our national
advertising campaign to bring the benefits of weight-bearing MRI, and its
necessity in the proper evaluation of back pain, to the attention of the
consumer and ultimately, referring physicians, hospitals, insurers and other
third party payors. The renewed national advertising campaign which began in
earnest on February 23, 2006 has helped to generate 31 sales leads. In addition,
there were 108 calls from patients who had experienced a failed back surgery.
The national advertising campaign has had a positive effect on Fonar's overall
sales activity and should result in increasing numbers of sales of Fonar Upright
MRI's. The principal reason for the decline in HMCA's revenues was the sale of
its physical therapy management business in July, 2005.
In addition, we are planning to expand our sales force, both in terms of
hiring more sales personnel and establishing a network of domestic distributors
(we already use distributors for foreign sales) under the direction of our
internal sales force.
We also are monitoring the performance of our existing users and plan to
establish teams to assist underperforming customers improve their scan volume.
Notwithstanding the disappointing MRI scanner sales revenues, the number of
units sold increased from one during the first quarter of fiscal 2006 to five
units during the second quarter and seven units during the third quarter of
fiscal 2006, which reflect Fonar's resumption of its advertising campaign. This
compares with eight sales during the first quarter of fiscal 2005, three sales
during the second quarter of fiscal 2005 and 11 sales during the third quarter
of fiscal 2005.
Importantly, we believe that our efforts to penetrate the hospital market
are beginning to show greater results. Subsequent to the end of the third
quarter of fiscal 2006, two Fonar Upright MRI(TM) scanners were sold to
hospitals, one of which is a member of a chain of hospitals. In addition we are
also in negotiations with another hospital chain for the sale of an Upright
MRI(TM) scanner. The Fonar Upright MRI(TM) scanner is the only scanner which
enables weight-bearing scans of the spine, which is critical in making a correct
diagnosis of spine diseases such as low back pain and therefore the key to
performing the correct surgery of the spine. There are approximately 800,000
surgical procedures performed on the spine each year as compared to
approximately 950,000 cardiac surgeries annually (including, stents, bypasses,
angioplasties, valve replacements, heart transplants and the like).
Forward Looking Statements
Certain statements made in this Quarterly Report on Form 10-Q are
"forward-looking statements" (within the meaning of the Private Securities
Litigation Reform Act of 1995) regarding the plans and objectives of Management
for future operations. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements of the Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. The forward-looking statements included herein are based on current
expectations that involve numerous risks and uncertainties. The Company's plans
and objectives are based, in part, on assumptions involving the expansion of
business. Assumptions relating to the foregoing involve judgments with respect
to, among other things, future economic, competitive and market conditions and
future business decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the control of the Company. Although the
Company believes that its assumptions underlying the forward-looking statements
are reasonable, any of the assumptions could prove inaccurate and, therefore,
there can be no assurance that the forward-looking statements included in this
Report will prove to be accurate. In light of the significant uncertainties
inherent in the forward-looking statement included herein, the inclusion of such
information should not be regarded as a representation by the Company or any
other person that the objectives and plans of the Company will be achieved.
Results of Operations
The Company operates in two industry segments: the manufacture and
servicing of medical (MRI) equipment, the Company's traditional business which
is conducted directly by Fonar, and diagnostic facilities management services,
which is conducted through Fonar's wholly-owned subsidiary, Health Management
Corporation of America ("HMCA"). During July 2005 HMCA sold the portion of its
business engaged in the management of physical therapy and rehabilitation
facilities.
Trends in the third quarter of fiscal 2006 include a decrease in product
sales revenues compared to the third quarter of fiscal 2005. Sales orders for
Stand-Up(TM) MRI scanners increased from one in the first fiscal quarter to five
in the second fiscal quarter (two of which were to related parties) and seven in
the third fiscal quarter (none of which were to related parties). The Company
will continue to focus on increased advertising and marketing efforts, including
adding additional sales personnel and distributors, to improve sales performance
in the last quarter of fiscal 2006 and fiscal 2007.
For the three month period ended March 31, 2006, as compared to the three
month period ended March 31, 2005, overall revenues from MRI product sales
decreased 90.3% ($1.7 million compared to $17.3 million). Unrelated party
scanner sales ($1.3 million compared to $15.6 million) decreased at a rate of
91.7% and related party scanner sales ($400,000 compared to $1.7 million)
decreased 77.2%. Service revenues, however, increased by 49.1% ($2.3 million
compared to $1.6 million) because of customers entering into service agreements
with Fonar for their scanners following the expiration of the warranty period on
their equipment. Overall, for the third quarter of fiscal 2006, revenues for the
medical equipment segment decreased by 79.4% to $4.0 million from $19.4 million
for the third quarter of fiscal 2005. The revenues generated by HMCA also
decreased, by 47.5% to $3.1 million for the third quarter of fiscal 2006 as
compared to $5.9 million for the third quarter of fiscal 2005. The decrease in
revenues recognized by HMCA resulted primarily from the sale of HMCA's business
of managing physical therapy and rehabilitation centers during July 2005.
For the nine month period ended March 31, 2006, as compared to the nine
month period ended March 31, 2005, overall revenues from MRI product sales
decreased 82.2% ($10.0 million compared to $56.5 million). Unrelated party
scanner sales ($7.1 million compared to $51.8 million) decreased at a rate of
86.3% and related party scanner sales ($2.9 million compared to $4.6 million)
decreased 36.9%. Service revenues, however, increased by 57.1% ($6.4 million
compared to $4.0 million) because of customers entering into service agreements
with Fonar for their scanners following the expiration of the warranty period on
their equipment. Overall, for the first nine months of fiscal 2006, revenues for
the medical equipment segment decreased by 71.7% to $17.6 million from $62.3
million for the first nine months of fiscal 2005. The revenues recognized by
HMCA also decreased, by 42.3% to $10.2 million for the first nine months of
fiscal 2006 as compared to $17.6 million for the first nine months of fiscal
2005. The decrease in revenues recognized by HMCA resulted primarily from the
sale of HMCA's business of managing physical therapy and rehabilitation centers
during July 2005.
There were approximately $2.7 million in foreign revenues for the first
nine months of fiscal 2006 as compared to approximately $5.1 million in foreign
revenues for the first nine months of fiscal 2005, representing a decrease in
foreign revenues of 47.1%.
We recognize MRI scanner sales revenues on the "percentage of completion"
basis, which means the revenues are recognized as the scanner is manufactured.
Revenues recognized in a particular quarter do not necessarily reflect new
orders or progress payments made by customers in that quarter. We build the
scanner as the customer meets certain benchmarks in its site preparation in
order to minimize the time lag between incurring costs of manufacturing and our
receipt of the cash progress payments from the customer which are due upon
delivery. Consequently, there can be a disparity between the revenues recognized
in a fiscal period and the number of product sales. Generally, the recognized
revenue results from revenues from a scanner sale being recognized in a fiscal
quarter or quarters following the quarter in which the sale was made.
Illustrating this point, the revenue from product sales for the first nine
months of fiscal 2006 decreased 82.2% from the first nine months of fiscal 2005
($10.0 million compared to $56.5 million). We received, however, orders for 13
Stand-Up(TM) (Upright(TM)) MRI scanners during the first nine months of fiscal
2006 as compared to orders for 22 Stand-Up(TM) (Upright(TM)) MRI scanners and
one Fonar 360(TM) MRI scanner during the first nine months of fiscal 2005
reflecting a lesser decrease of 43.5% in scanner orders.
We believe the decrease in product sales revenues reflect the large
variation in sales revenue that is typical of the sale of high unit cost capital
equipment, which variation is characteristic of Fonar's 28 year experience
selling MRI scanning systems.
Service and repair revenues increased by 49.1%, from $1.6 million for the
third quarter of fiscal 2005 to $2.3 million for the third quarter of fiscal
2006. License fees and royalties decreased from $585,000 for the third quarter
of fiscal 2005 to $0 million for the third quarter of fiscal 2006. The $585,000
in 2005 represented an amortization of license fees which were fully amortized
at June 30, 2005.
Service and repair revenues increased by 57.1%, from $4.0 million for the
first nine months of fiscal 2005 to $6.4 million for the first nine months of
fiscal 2006. License fees and royalties decreased by 30.1% from $1.8 million for
the first nine months of fiscal 2005 to $1.2 million for the first nine months
of fiscal 2006.
The increases in service and repair revenues are occurring because after
the warranty on the MRI scanner expires, the owner will ordinarily enter into a
service contract with us to assure continued coverage. We anticipate that for
this reason there will continue to be increases in service revenues as
warranties on installed scanners expire over time.
Costs related to product sales decreased by 80.9% from $11.0 million in the
third quarter of fiscal 2005 to $2.1 million in the third quarter of 2006,
reflecting the corresponding decrease in product sales revenues. Costs related
to providing service increased remained constant at $1.4 million in the third
quarter of fiscal 2005 and in the third quarter of 2006, notwithstanding the
increase in service revenues.
Costs related to product sales decreased by 73.1% from $35.7 million in the
first nine months of fiscal 2005 to $9.6 million in the first nine months of
fiscal of 2006, reflecting the corresponding decrease in product sales. Costs
related to providing service increased 10.9% from $3.8 million in the first nine
months of fiscal 2005 to $4.2 million in the first nine months of 2006.
In brief, costs are incurred concurrently with revenues in accordance with
the percentage of completion method.
Service and repair revenues increased at a materially higher rate than the
costs related to providing service and repairs. Service contract prices are
fixed for the term of the contract, which are usually for a term of one year. We
believe that an important factor in keeping service costs down is our ability to
monitor the performance of customers' scanners from our facilities in Melville
on a daily basis and to detect and repair any irregularities before more serious
problems result. We also believe the low cost of providing service reflects the
high quality of our products.
Overall, our operating loss for our medical equipment segment was $16.8
million for the first nine months of fiscal 2006 as compared to operating income
of $1.4 million for the first nine months of fiscal 2005.
HMCA revenues decreased in the third quarter of fiscal 2006, by 47.5% to
$3.1 million from $5.9 million for the third quarter of fiscal 2005. For the
first nine months of fiscal 2006, HMCA revenues decreased by 42.3% to $10.2
million from $17.6 million for the first nine months of fiscal 2005. HMCA is
seeking to increase revenues from the MRI facilities by continuing its program
of replacing older scanners at the sites we manage with Stand-Up(TM)
(Upright(TM)) MRI scanners. We now manage nine sites equipped with Stand- Up(TM)
MRI scanners, and we are planning to open one new site with Stand-Up(TM) MRI
scanners within the next twelve months, which would bring the total number of
facilities with Stand-Up(TM) MRI scanners we manage to ten. HMCA experienced an
operating loss of $4.1 million for the first nine months of fiscal 2006 compared
to operating income of $730,000 for the first nine months of fiscal 2005. This
was principally the result of a payment of $1.6 million for the termination of
two employment agreements in connection with the sale by HMCA of its physical
therapy and rehabilitation facility management business and the loss of revenues
resulting from the sale of that business.
HMCA cost of revenues for the third quarter of fiscal 2006 decreased to
$2.1 million as compared to $3.7 million for the third quarter of fiscal 2005,
which is also principally the result of HMCA's sale of its physical therapy and
rehabilitation facility management business. HMCA cost of revenues for the first
nine months of fiscal 2006 decreased to $7.3 million as compared to $10.9
million for the first nine months of fiscal 2005.
Sale of Physical Therapy and Rehabilitation Facility Management Business
Notwithstanding our continuing efforts to increase revenues from the
management of MRI scanning facilities, HMCA's revenues declined because of the
sale of its business of managing physical therapy and rehabilitation practices.
The sale was completed on July 28, 2005. This sale was made in connection with
HMCA's decision to focus on the management of diagnostic imaging facilities.
The sale was made pursuant to an asset purchase agreement to Health Plus
Management Services, L.L.C. There is no material relationship between Health
Plus and Fonar, HMCA, or any of their respective subsidiaries, directors or
officers, or associates of any such person. The two principals of Health Plus
were employed by HMCA up to the time of the closing of the transaction. In
consideration for the termination of their employment agreements, these two
individuals each became entitled to receive $800,000. In addition, each became
entitled to receive $200,000 for billing and collection services to be provided
on behalf of HMCA with respect to a portion of the accounts receivable of
certain physical therapy and rehabilitation facilities which arose during the
period when we were engaged in the management of those facilities. The
$1,000,000 payable to each of these individuals was payable at our option in
shares of Fonar common stock.
The purchase price under the asset purchase agreement was $6.6 million,
payable pursuant to a promissory note in 120 monthly installments commencing on
August 28, 2005. The first twelve installments are interest only and the
remaining 108 payments will consist of equal installments of principal and
interest in the amount of $76,014 each. The note is subject to prepayment
provisions to the extent Health Plus resells all or part of the assets and
business or utilizes the assets sold as collateral in any debt financing. A loss
from the sale of $143,598 has been recorded during the quarter ended September
30, 2005. The note provides for interest at 5% per annum. The $6.6 million note
was valued at $6,078,068 as a result of a discount for the below market interest
rate.
As our consolidated revenues decreased by 72.0% to $7.1 million for the
third quarter of fiscal 2006 from $25.3 million for the third quarter of fiscal
2005, the total costs and expenses decreased by 43.0 % to $14.5 million for the
third quarter of fiscal 2006 from $25.4 million for the third quarter of fiscal
2005. The decline in revenue was the primary reason we were unable to achieve
profitability in the third quarter of fiscal 2006. For the first nine months of
fiscal 2006 the consolidated revenues decreased by 65.2% to $27.8 million from
$79.9 million for the first nine months of fiscal 2005.
Selling, general and administrative expenses decreased by 6.9 % from $20.0
million in the first nine months of fiscal 2005 to $18.6 million in the first
nine months of fiscal 2006. The compensatory element of stock issuances
decreased by 46.0% from $2.5 million in the first nine months of fiscal 2005 to
$1.3 million in the first nine months of fiscal 2006 which is now included in
selling general and administrative expenses. This primarily reflected a lesser
use of Fonar's stock in lieu of cash to pay employees, consultants and
professionals for services.
Research and development expenses increased by 21.9 % to $5.2 million for
the first nine months of fiscal 2006 as compared to $4.3 million for the first
nine months of fiscal 2005. Much of the increase was due to increased research
and development on our Fonar 360(TM) MRI scanner.
Interest expense in the first nine months of fiscal 2006 increased by 19.6%
to $214,000 from $179,000 for the first nine months of fiscal 2005.
Inventories decreased by 22.2% to $7.7 million at March 31, 2006 as
compared to $9.8 million at June 30, 2005 as the Company's product sales
revenues decreased and we decreased our purchase of raw materials and
components.
Costs and estimated earnings in excess of billings on uncompleted contracts
decreased by 57.5% to $4.5 million at March 31, 2006 from $10.5 million at June
30, 2005. This decrease resulted from our receipt of installment payments upon
delivery to customers whose sites were prepared to receive deliveries.
Management fee and medical receivables and accounts receivable decreased by
9.4% to $19.2 million at March 31, 2006 from $21.2 million at June 30, 2005,
primarily due to an increased bad debt allowance on the Company's management fee
and medical receivables and an increase in accounts receivable from the medical
segment.
Our operating and net loss were $20.9 million and $21.0 million,
respectively, for the first nine months of fiscal 2006 as compared to operating
and net income of $2.1 million and $1.4 million, respectively, for the first
nine months of fiscal 2005.
The overall trends reflected in the results of operations for the first
nine months of fiscal 2006 are a decrease in revenues from product sales, as
compared to the first nine months of fiscal 2005 ($10.0 million for the first
nine months of fiscal 2006 as compared to $56.5 million for the first nine
months of fiscal 2005), and a decrease in MRI equipment segment revenues
relative to HMCA revenues ($17.6 million or 63% from the MRI equipment segment
as compared to $10.2 million or 37% from HMCA, for the first nine months of
fiscal 2006, as compared to $62.3 million or 78% from the MRI equipment segment
and $17.6 million or 22%, from HMCA, for the first nine months of fiscal 2005).
In addition, we experienced a decrease in unrelated party sales relative to
related party sales in our medical equipment product sales ($7.1 million or 71%
to unrelated parties and $2.9 million or 29% to related parties for the first
nine months of fiscal 2006 as compared to $51.8 million, or 92% to unrelated
parties and $4.6 million or 8% to related parties for the first nine months of
fiscal 2005).
We are committed to reversing the trends we have experienced in the first
nine months in fiscal 2006. Nevertheless, factors beyond our control, such as
the timing and rate of market growth which depend on economic conditions, and
unexpected expenditures or the timing of such expenditures, make it impossible
to forecast future operating results. We believe we are pursuing the correct
policies which should prove successful in improving the Company's operating
results.
The Company's Stand-Up(TM), and Fonar-360(TM) MRI scanners, together with
the Company's works-in-progress, are intended to significantly improve the
Company's competitive position.
The Company's Stand-Up(TM) scanner, which operates at 6000 gauss (.6 Tesla)
field strength, allows patients to be scanned while standing or reclining. As a
result, for the first time, MRI is able to be used to show abnormalities and
injuries under full weight-bearing conditions, particularly the spine and
joints. A floor-recessed elevator brings the patient to the height appropriate
for the targeted image region. A custom- built adjustable bed will allow
patients to sit or lie on their backs, sides or stomachs at any angle.
Full-range-of-motion studies of the joints in virtually any direction will be
possible, an especially promising feature for sports injuries.
The Stand-Up(TM) will also be useful for MRI directed neuro-surgical
procedures as the surgeon would have unhindered access to the patient's head
when the patient is supine with no restrictions in the vertical direction. This
easy-entry, mid-field-strength scanner should be ideal for trauma centers where
a quick MRI-screening within the first critical hour of treatment will greatly
improve patients' chances for survival and optimize the extent of recovery.
The Fonar 360(TM) is an enlarged room sized magnet in which the floor,
ceiling and walls of the scan room are part of the magnet frame. This is made
possible by Fonar's patented Iron-Frame(TM) technology which allows the
Company's engineers to control, contour and direct the magnet's lines of flux in
the patient gap where wanted and almost none outside of the steel of the magnet
where not wanted. Consequently, this scanner allows surgeons and other
interventional physicians to walk inside the magnet and achieve 360 degree
access to the patient to perform interventional procedures.
The Fonar 360(TM) is presently marketed as a diagnostic scanner and is
sometimes referred to as the Open Sky(TM) MRI. In its Open Sky(TM) version, the
Fonar 360(TM) serves as an open patient friendly scanner which allows 360 degree
access to the patient on the scanner bed. To optimize the patient-friendly
character of the Open Sky(TM) MRI, the walls, floor, ceiling and magnet poles
are decorated with landscape murals. The patient gap is twenty inches and the
magnetic field strength, like that of FONAR's Stand-Up(TM) and QUAD(TM) MRI
scanner, is 0.6 Tesla.
In the future, we expect the Fonar 360(TM) to function as an interventional
MRI. The enlarged room sized magnet and 360 access to the patient afforded by
the Fonar 360(TM) would permit surgeons to walk into the magnet and perform
interventions on the patient inside the magnet. Most importantly the exceptional
quality of the MRI image and its capacity to exhibit tissue detail on the image,
can then be obtained real time during the procedure to guide the
interventionalist. Thus surgical instruments, needles, catheters, endoscopes and
the like could be introduced directly into the human body and guided to the
malignant lesion by means of the MRI image. The number of inoperable lesions
should be greatly reduced by the availability of this new capability. Most
importantly treatment can be carried directly to the target tissue. The
interventional features of the Fonar 360(TM) are expected to be implemented by
Oxford Nuffield Orthopedic Center in Oxford U.K. in the near future. A full
range of MRI compatible surgical instruments using ceramic cutting tools and
beryllium-copper materials are available commercially.
The Company expects marked demand for its most commanding MRI products, the
Stand- Up(TM) and the Fonar 360(TM), first for their exceptional features in
patient diagnosis and treatment. These scanners additionally provide improved
image quality and higher imaging speed because of their higher field strength of
..6 Tesla. The geometry of the Stand-Up(TM) MRI as compared to a single coil, or
multiple coils on only one axis and its transverse magnetic field enables the
use of two detector rf coils operating in quadrature which increases the Stand-
Up(TM) signal to noise ratio by 40% providing a signal to noise ratio equal to a
..84T recumbent only MRI scanner.
Liquidity and Capital Resources
Cash, cash equivalents and marketable securities decreased from $14.9
million at June 30, 2005 to $10.0 million at March 31, 2006. Principal uses of
cash during the first nine months of fiscal 2006 included capital expenditures
for property and equipment of $1.6 million, repayment of long-term debt and
capital lease obligations in the amount of $255,000, capitalized software
development costs of $557,000 and capitalized patent and copyright costs of
$371,000, and a decrease in accounts payable of $3.7 million.
Marketable securities approximated $6.4 million as at March 31, 2006, as
compared to $9.4 million at June 30, 2005. This reduction represents the
maturation of marketable securities which have not been reinvested and the
proceeds of which are available to fund operations if needed. At March 31, 2006,
our investments in U.S. Government obligations were $2.8 million, our
investments in corporate and government agency bonds were $2.8 million and our
investments in certificates of deposit and deposit notes were $675,000. The
investments made have had the intended effect of maintaining a stable investment
portfolio.
Cash used in operating activities for the first nine months of fiscal 2006
approximated $2.7 million. Cash used in operating activities was attributable
primarily to the net loss of $21.0 million and the decrease in accounts payable
of $3.7 million, which were offset by a decrease in costs and estimated earnings
in excess of billings on uncompleted contracts of $6.1 million, a decrease in
inventories of $2.2 million and the issuance of stock in lieu of cash for
termination of two employment contracts of $1.6 million and the issuance of
stock for compensation, costs and expenses in lieu of cash in the amount of $4.3
million.
Cash provided by investing activities for the first nine months of fiscal
2006 approximated $487,000. The principal source of cash from investing
activities during the first nine months of fiscal 2006 consisted of the sale of
marketable securities of $3.2 million, offset by expenditures for property and
equipment of approximately $1.6 million and capitalized software and patent
costs of approximately $928,000.
Cash provided by financing activities for the first nine months of fiscal
2006 approximated $326,000. The sources of cash from financing activities were
net proceeds from exercises of stock options and warrants of $662,000. The
principal uses of cash in financing activities during the first nine months of
fiscal 2006 consisted of repayment of principal on long-term debt and capital
lease obligations of approximately $255,000 and distributions to holders of
minority interests of $604,000.
The Company's obligations and the periods in which they are scheduled to
become due are set forth in the following table:
Due in
Less Due Due Due
than 1 in 1-3 in 4-5 after 5
Obligation Total year years years years
- -------------- ----------- ---------- ---------- ---------- ----------
Long-term debt $ 478 $ -- $ -- $ -- $ 478
Capital lease
Obligation 894 229 397 258 10
Operating
Leases 8,825 2,247 4,190 1,332 1,056
----------- ---------- ---------- ---------- ----------
Total cash
Obligations $ 10,197 $ 2,476 $ 4,587 $ 1,590 $ 1,544
=========== ========== ========== ========== ==========
Total liabilities decreased by 2.2% to $23.2 million at March 31, 2006 from
$23.7 million at June 30, 2005.
We experienced an increase in long-term debt from $966,000 at June 30, 2005
to $1.1 million at March 31, 2006, an increase in unearned revenue on service
contracts from $3.8 million to $5.4 million at June 30, 2005 to March 31, 2006,
an increase in billings in excess of costs and estimated earnings on uncompleted
contracts from $454,000 at June 30, 2005 to $1.2 million at March 31, 2006, a
decrease in accounts payable from $8.5 million at June 30, 2005 to $4.8 million
at March 31, 2006, an increase in customer advances from $1.7 million at June
30, 2005 to $3.5 at March 31, 2006 and a decrease in other current liabilities
from $7.5 million at June 30, 2005 to $6.5 million at March 31, 2006. Long-term
debt increased primarily as a result of a loan to purchase real estate for an
MRI facility managed by HMCA.
As of March 31, 2006, the total of $6.5 million in other current
liabilities included primarily accrued salaries and payroll taxes of $1.4
million, accrued royalties of $825,000 and excise and sales taxes of $2.3
million.
Our working capital approximated $21.7 million as of March 31, 2006, as
compared to working capital of $36.2 million as of June 30, 2005, decreasing by
40.2%. This resulted principally from a decrease in accounts receivable of $2.0
million ($21.2 million at June 30, 2005 as compared to $19.2 million at March
31, 2006), an increase of customer advances of $1.8 million ($1.7 million at
June 30, 2005 as compared to $3.5 million at March 31, 2006) along with a
decrease in inventories of $2.2 million ($9.8 million at June 30, 2005 as
compared to $7.7 million at March 31, 2006).
With respect to current liabilities, the current portion of long-term
debt decreased from $425,000 at June 30, 2005 to $229,000 at March 31, 2006,
and billings in excess of costs and estimated earnings on uncompleted contracts
increased from $454,000 at June 30, 2005 to $1.2 million at March 31, 2006.
Customer advances increased from $1.7 million at June 30, 2005 to $3.5 million
at March 31, 2006 and accounts payable decreased from $8.5 million at June 30,
2005 to $4.8 million at March 31, 2006.
In order to conserve our capital resources, we have issued common stock
under our stock bonus and stock option plans to compensate employees and non-
employees for services rendered. In the first nine months of fiscal 2006, the
compensatory element of stock issuances was $1.3 million as compared to $2.5
million for the first nine months of fiscal 2005. Utilization of equity in lieu
of cash compensation has improved our liquidity since it increases cash
available for other expenditures. In addition, we used stock to pay $ 1.6
million for the termination of two employment agreements terminated in
connection with the sale of HMCA's physical therapy and rehabilitation facility
management business.
Fonar's capital resources are expected to improve as Fonar's MRI scanner
products gain wider market recognition and acceptance and produce increased
product sales. The Company is focusing on increased advertising and marketing to
increase demand for its products.
Inventories decreased by $2.2 million ($9.8 million at June 30, 2005 as
compared to $7.7 million at March 31, 2006) resulting from a decrease in the
purchasing of raw materials and components and in filling our backlog of orders.
Fonar has not committed to making additional capital expenditures in the
2006 fiscal year other than its intention to continue research and development
expenditures at current levels. HMCA also expects to incur capital expenditures
of approximately $300,000 to lease premises and to construct and furnish one new
Stand-Up(TM) MRI facilities, which would bring the total number of Stand-Up(TM)
MRI facilities managed by HMCA to ten.
Our business plan calls for a continuing emphasis on providing our
customers with enhanced equipment service and maintenance capabilities and
delivering state-of-the-art, innovative and high quality equipment upgrades at
competitive prices.
Our principal source of liquidity has been cash flows provided by
operations. We currently expect this to continue. At March 31, 2006, we had
working capital of $21.7 million. For the nine months ended March 31, 2006, we
incurred a net loss of $21 million which included non-cash charges of $10.4
million.
In order to conserve our capital resources we have and will continue to
issue, from time to time, common stock and stock options to compensate employees
and non-employees for services rendered. The Company is focusing on increased
advertising and marketing campaigns and distribution programs to increase the
demand for Fonar's products. Management anticipates that Fonar's capital
resources will improve as Fonar's MRI scanner products gain wider market
recognition and acceptance resulting in increased product sales.
Given our March 31, 2006 cash and marketable securities balance of $9.9
million and our forecasted cash requirements, we anticipate that our existing
capital resources, funds generated from operations and funds expected to be
received from note repayments, will be sufficient to satisfy our cash flow
requirements through at least March 31, 2007. Should sales be less than forecast
and expenses higher than anticipated, the Company may need to seek alternative
sources of funds through the issuance of equity or debt financing or other
alternatives including streamlining operations.
The Company received written notification from The Nasdaq Stock Market on
December 22, 2005 that the bid price of its common stock for the last 30
consecutive trading days had closed below the minimum $1.00 per share required
for continued listing under Nasdaq Marketplace Rule 4310(c)(4) (the "Rule").
Pursuant to Nasdaq Marketplace Rule 4310(c)(8)(D), the Company has been provided
an initial period of 180 calendar days, or until June 20, 2006, to regain
compliance. The notice states the Nasdaq staff (the "Staff") will provided
written notification that the Company has achieved compliance with the Rule if
at any time before June 20, 2006 the bid price of the Company's common stock
closes at $1.00 per share or more for a minimum of 10 consecutive business days.
If the Company cannot demonstrate compliance with the Rule by June 20,
2006, the Staff will determine whether the Company meets the Nasdaq Capital
Market initial listing criteria as set forth in Marketplace Rule 4310(c), except
for the bid price requirement. If the Company meets the initial listing
criteria, the Staff will notify the Company that it has been granted an
additional 180 calendar days compliance period. FONAR currently complies with
the requirements for initial listing on The Nasdaq Capital Market, except for
the $1.00 minimum closing bid price. If the Company is not eligible for an
additional compliance period, the Staff will provide written notice that the
Company's securities will be delisted. At that time, the Company may appeal the
Staff's determination to delist its securities to a Listing Qualifications
Panel.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our investments are in fixed rate instruments. Below is a tabular
presentation of the maturity profile of the fixed rate instruments held by us at
March 31, 2006.
INTEREST RATE SENSITIVITY
PRINCIPAL AMOUNT BY EXPECTED MATURITY
WEIGHTED AVERAGE INTEREST RATE
Investments
Year of in Fixed RateWeighted Average
Maturity Instruments Interest Rate
3/31/07 $ 1,100,000 3.60%
3/31/08 1,650,000 3.78%
3/31/09 1,500,000 3.65%
3/31/10 2,144,499 3.35%
3/31/11 200,000 4.44%
------------------
Total: $ 6,594,499
=========
Fair Value
at 3/31/06$ 6,319,712
=========
All of our revenue, expense and capital purchasing activities are
transacted in United States dollars.
See Note 13 to the consolidated Financial Statements in our Form 10-K as of
and for the year ended June 30, 2005 for information on long-term debt.
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures.
The Company maintains controls and procedures designed to ensure that
information required to be disclosed in the reports that it files or submits
under the Securities Exchange Act of 1934 is recorded, processed, summarized and
reported within the time periods specified in the rules and forms of the
Securities and Exchange Commission. Based upon their evaluation of those
controls and procedures performed as of the end of the period covered by this
report, the principal executive and acting principal financial officer of the
Company concluded that disclosure controls and procedures were effective.
(b) Change in internal controls.
The Company continues to enhance its controls and procedures related to the
financial reporting process, improvements that were established during the
latter part of fiscal 2005. This included hiring an outside consultant to assist
with technical accounting and reporting issues, developing more standardized
closing procedures and implementing a more formal process for documenting the
weekly management meetings to review operating performance and results.
There have been no changes in our internal control over financial reporting
that occurred during the most recent fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control
over financial reporting.
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings: There were no material changes in litigation for the
first six months of fiscal 2006.
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds: None
Item 3 - Defaults Upon Senior Securities: None
Item 4 - Submission of Matters to a Vote of Security Holders: None
Item 5 - Other Information: None
Item 6 - Exhibits and Reports on Form 8-K:
Exhibit 31.1 Certification See Exhibits
Exhibit 32.1 Certification See Exhibits
8-K (earnings press release) filed on September 29, 2005
8-K (earning press release) filed on November 8, 2005
8-K (notice of failure to maintain bid price of common stock at $1.00
for 30 days) on December 23, 2005
8-K (earnings press release) filed on February 10, 2006
FONAR CORPORATION AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
FONAR CORPORATION
(Registrant)
By: /s/ Raymond V. Damadian
Raymond V. Damadian
President & Chairman
Dated: May 11, 2006